Roivant Sciences Shares Jump 3.7% After Cowen Reiterates Buy Rating
Cowen & Co. reiterated its Buy rating for Roivant Sciences, highlighting growth potential and engagement at the TD Cowen 46th Annual Health Care Conference. Shares rose about 3.7% today, while market capitalization stands near $20.68 billion on trading volume of roughly 4.25 million shares.
1. Cowen Maintains Buy Rating
Cowen & Co. reiterated its Buy rating for Roivant Sciences during the TD Cowen 46th Annual Health Care Conference, citing the company’s innovative drug development model and growth potential across its therapeutic-focused subsidiaries.
2. Shares Rise 3.7% in Trading Session
Following the rating reiteration, Roivant’s shares increased approximately 3.73% in today’s session, reaching an intraday high of $29.64 and a low of $28.44, reflecting robust investor interest.
3. Market Capitalization and Volume Metrics
Roivant’s market capitalization stands at approximately $20.68 billion with trading volume near 4.25 million shares, underscoring significant liquidity and investor engagement.
4. One-Year Stock Performance
Over the past year, Roivant stock has traded between $8.73 and $29.71, illustrating notable volatility and potential reward opportunities for investors.